because of the reported high sensitivity of acute promyelocytic leukemia to daunorubicin , we treated 27 consecutive , newly diagnosed , acute promyelocytic leukemia ( apl ) patients with the new anthracycline idarubicin ( ida ) as induction therapy .
C0011015
daunorubicin
C0020789
idarubicin